These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1228 related items for PubMed ID: 19095129

  • 21. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
    Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S.
    Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
    [Abstract] [Full Text] [Related]

  • 22. Bosentan for patients with chronic thromboembolic pulmonary hypertension.
    Vassallo FG, Kodric M, Scarduelli C, Harari S, Potena A, Scarda A, Piattella M, Cassandro R, Confalonieri M.
    Eur J Intern Med; 2009 Jan; 20(1):24-9. PubMed ID: 19237088
    [Abstract] [Full Text] [Related]

  • 23. Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A systemic review and meta-analysis.
    Chen X, Zhai Z, Huang K, Xie W, Wan J, Wang C.
    Clin Respir J; 2018 Jun; 12(6):2065-2074. PubMed ID: 29393580
    [Abstract] [Full Text] [Related]

  • 24. Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis.
    Becattini C, Manina G, Busti C, Gennarini S, Agnelli G.
    Thromb Res; 2010 Jul; 126(1):e51-6. PubMed ID: 20172593
    [Abstract] [Full Text] [Related]

  • 25. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
    McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ.
    Am J Respir Crit Care Med; 2006 Dec 01; 174(11):1257-63. PubMed ID: 16946127
    [Abstract] [Full Text] [Related]

  • 26. Survival with first-line bosentan in patients with primary pulmonary hypertension.
    McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, Rainisio M, Simonneau G, Rubin LJ.
    Eur Respir J; 2005 Feb 01; 25(2):244-9. PubMed ID: 15684287
    [Abstract] [Full Text] [Related]

  • 27. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension.
    Surie S, Reesink HJ, Marcus JT, van der Plas MN, Kloek JJ, Vonk-Noordegraaf A, Bresser P.
    Clin Cardiol; 2013 Nov 01; 36(11):698-703. PubMed ID: 24037998
    [Abstract] [Full Text] [Related]

  • 28. Tadalafil therapy for pulmonary arterial hypertension.
    Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ, Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group.
    Circulation; 2009 Jun 09; 119(22):2894-903. PubMed ID: 19470885
    [Abstract] [Full Text] [Related]

  • 29. Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
    Reesink HJ, van der Plas MN, Verhey NE, van Steenwijk RP, Kloek JJ, Bresser P.
    J Thorac Cardiovasc Surg; 2007 Feb 09; 133(2):510-6. PubMed ID: 17258590
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial.
    Baughman RP, Culver DA, Cordova FC, Padilla M, Gibson KF, Lower EE, Engel PJ.
    Chest; 2014 Apr 09; 145(4):810-817. PubMed ID: 24177203
    [Abstract] [Full Text] [Related]

  • 35. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.
    J Am Coll Cardiol; 2010 May 04; 55(18):1915-22. PubMed ID: 20430262
    [Abstract] [Full Text] [Related]

  • 36. Bosentan therapy for portopulmonary hypertension.
    Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, Winkler J.
    Eur Respir J; 2005 Mar 04; 25(3):502-8. PubMed ID: 15738295
    [Abstract] [Full Text] [Related]

  • 37. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses.
    Karavolias GK, Georgiadou P, Gkouziouta A, Kariofillis P, Karabela G, Tsiapras D, Sbarouni E, Chaidaroglou A, Degiannis D, Adamopoulos S, Voudris V.
    Expert Opin Ther Targets; 2010 Dec 04; 14(12):1283-9. PubMed ID: 20958219
    [Abstract] [Full Text] [Related]

  • 38. Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options.
    Lang IM.
    Eur Respir Rev; 2009 Mar 04; 18(111):24-8. PubMed ID: 20956119
    [Abstract] [Full Text] [Related]

  • 39. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, Mühler EG, Ewert P, Lange PE, Berger F, Schulze-Neick I.
    Eur J Clin Invest; 2006 Sep 04; 36 Suppl 3():32-8. PubMed ID: 16919008
    [Abstract] [Full Text] [Related]

  • 40. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy.
    Kramm T, Eberle B, Guth S, Mayer E.
    Eur J Cardiothorac Surg; 2005 Dec 04; 28(6):882-8. PubMed ID: 16242948
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 62.